Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Target Advancement Program, 2016
    Targeting the Transcriptional Regulator of Autophagy LMX1B for Parkinson's Disease Therapeutic Development

    Study Rationale:
    LMX1B is a transcription factor that plays an essential role in the development of dopaminergic neurons. We have recently described a new role for LMX1B in dopaminergic neurons as a...

  • Target Advancement Program, 2016
    Role of LRRK2 in GCase-mediated Alterations in Lysosome Function and Alpha-synuclein Metabolism

    Study Rationale:
    Mutations in the lysosomal (enzyme storage unit) enzyme GCase are associated with an increased risk of Parkinson's disease (PD) and cause alpha-synuclein (protein associated with...

  • Improved Biomarkers and Clinical Outcome Measures, 2016
    Brainstem and Olfactory System Biomarkers of Early Parkinson's Disease

    Study Rationale:
    There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology...

  • Target Advancement Program, 2016
    GADD34 Inhibition as a Neuroprotective Strategy in Parkinson's Disease

    The lack of disease-modifying therapies is a crucial deficiency in the treatment of Parkinson disease (PD). Using cellular models of PD, we have identified the protein GADD34 as a novel potential...

  • Research Grant, 2016
    Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates

    Study Rationale:
    The kinase (protein regulator) LRRK2 is thought to play an important role in both familial (inherited) and sporadic (no known cause) Parkinson's disease (PD). Unfortunately, a lack of...

  • Target Advancement Program, 2016
    Targeting RER1 in Models of Parkinson's Disease

    Study Rationale:
    Abnormal build-up of the protein alpha-synuclein in Parkinson's disease (PD) has been linked to cell stress and death. These deficits can be rescued by expressing certain proteins...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.